Regeneron Pharmaceuticals Inc. reached a deal with the Trump administration to lower drug costs for some Americans and won US approval for its gene therapy to treat a rare form of deafness, according to a person who declined to be identified in order to speak before the announcement was made.
Regeneron was the last of the major drug companies that President Donald Trump had targeted as part of his plan to lower US costs in line with other developed nations.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.